Olanzapine treatment for tardive dyskinesia in schizophrenia patients: a prospective clinical trial with patients randomized to blinded dose reduction periods

Progress in Neuro-psychopharmacology & Biological Psychiatry
Bruce J KinonHong Liu-Seifert

Abstract

Tardive dyskinesia (TD) is a potentially persistent and disabling abnormal involuntary movement disorder. The aim of this 8-month study was to determine if olanzapine treatment could lead to a significant and persistent reduction in preexisting TD. Eligible schizophrenia patients met restricted Research Diagnosis criteria of TD requiring, in part, a rating of at least moderate severity (score > or = 3) in one or more of seven body regions on the Abnormal Involuntary Movement Scale (AIMS). Patients received olanzapine, 5-20 mg/day, for 8 months. During this period, they underwent one to two dose reduction periods under blinded conditions. Concurrent changes in TD, psychopathology, parkinsonism and akathisia were assessed with the AIMS, the Positive and Negative Syndrome Scale (PANSS), and the Simpson-Angus and Barnes Akathisia Scales, respectively. A significant reduction in mean AIMS total score was demonstrated at endpoint (n = 92; p < 0.001) as well as at each visit (p < 0.001) and as early as Week 1 on olanzapine. Approximately 70% of patients no longer met the restricted Research Diagnostic criteria for persistent TD (RD-TD) after 8 months of treatment. No statistically significant rebound worsening of TD was found during e...Continue Reading

References

May 1, 1979·Archives of General Psychiatry·D V JesteR J Wyatt
Jan 1, 1979·Schizophrenia Bulletin·D V Jeste, R J Wyatt
Jan 31, 1978·Psychopharmacology·G M SimpsonR K Shrivastava
Jan 1, 1978·The American Journal of Psychiatry·T R BarnesP J Taylor
Oct 1, 1990·The British Journal of Psychiatry : the Journal of Mental Science·W M GlazerD C Moore
May 1, 1989·The British Journal of Psychiatry : the Journal of Mental Science·T R Barnes
Jan 1, 1987·Acta Psychiatrica Scandinavica·H A Youssef, J L Waddington
Aug 1, 1988·Journal of Clinical Psychopharmacology·D V JesteR J Wyatt
Jan 1, 1970·Acta Psychiatrica Scandinavica. Supplementum·G M Simpson, J W Angus
Dec 1, 1980·Archives of General Psychiatry·J M Smith, R J Baldessarini
Apr 1, 1982·Archives of General Psychiatry·N R Schooler, J M Kane
Jan 1, 1984·Clinical Neuropharmacology·H L KlawansA Barr
Dec 19, 1983·Life Sciences·H RosengartenA J Friedhoff
Sep 1, 1995·Archives of General Psychiatry·D V JesteL A McAdams
Jan 1, 1994·Schizophrenia Bulletin·C E BoumansF G Zitman
May 1, 1993·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·R CavallaroE Smeraldi
Aug 1, 1996·Prostaglandins, Leukotrienes, and Essential Fatty Acids·R D Reddy, J K Yao
Jan 1, 1997·Schizophrenia Bulletin·T E HansenW F Hoffman
Mar 24, 1998·Archives of General Psychiatry·K H LittrellC D Peabody
Mar 31, 1998·The British Journal of Psychiatry : the Journal of Mental Science·J O'Brien, R Barber
Jul 31, 1998·Progress in Neuro-psychopharmacology & Biological Psychiatry·G W DalackJ H Meador-Woodruff
Nov 13, 1998·The American Journal of Psychiatry·M G WoernerJ M Kane
Jun 12, 1999·Journal of the American Geriatrics Society·D V JesteM P Caligiuri
Jul 3, 1999·Annals of Internal Medicine·A Herrán, J L Vázquez-Barquero
Nov 26, 1999·European Psychiatry : the Journal of the Association of European Psychiatrists·L LykourasG N Christodoulou
Feb 9, 2000·The Journal of Clinical Psychiatry·J Ananth, J Kenan
Jun 6, 2000·Biological Psychiatry·C E MarxA L Morrow
Jun 30, 2000·The American Journal of Psychiatry·D V JesteR A Martinez
Apr 4, 2001·The International Journal of Neuropsychopharmacology·Michele RajaGiovanni Maisto
Nov 20, 2001·International Clinical Psychopharmacology·O UzunA Ozsahin
Jan 17, 2002·The Annals of Pharmacotherapy·I SchillevoortH G Leufkens
Feb 19, 2002·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Junji IchikawaHerbert Y Meltzer
Apr 3, 2002·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Sudabeh Shirazi-SouthallGeorge G Nomikos

❮ Previous
Next ❯

Citations

Jul 20, 2007·Schizophrenia Bulletin·R A RosenheckMichael Sernyak
Apr 26, 2014·PloS One·Maarten BakMarjan Drukker
Sep 8, 2010·The Journal of Clinical Psychiatry·Stanley N CaroffUNKNOWN CATIE Investigators
Jun 19, 2012·General Hospital Psychiatry·John LallyElizabeth Walsh
Oct 2, 2008·The British Journal of Psychiatry : the Journal of Mental Science·Del D MillerUNKNOWN Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators
Sep 11, 2009·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·E N RizosL Lykouras
May 24, 2011·Journal of Psychosocial Nursing and Mental Health Services·Robert H Howland
Oct 4, 2005·Expert Opinion on Pharmacotherapy·Peter F Buckley
Dec 12, 2012·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·Alkomiet HasanUNKNOWN WFSBP Task force on Treatment Guidelines for Schizophrenia
Sep 28, 2010·Progress in Neuro-psychopharmacology & Biological Psychiatry·Görkem Karakas UgurluSadullah Saglam
Apr 29, 2016·Clinical Psychopharmacology and Neuroscience : the Official Scientific Journal of the Korean College of Neuropsychopharmacology·Satyakam Mohapatra
Jun 6, 2007·Journal of Geriatric Psychiatry and Neurology·Ilya LipkovichVicki Poole Hoffmann
Apr 27, 2017·Expert Opinion on Pharmacotherapy·Daniel P WitterUma Suryadevara
Jul 11, 2014·Journal of Geriatric Psychiatry and Neurology·Bruce J KinonVirginia Stauffer
Feb 7, 2018·The Cochrane Database of Systematic Reviews·Hanna BergmanKarla Soares-Weiser
Dec 24, 2005·Harvard Review of Psychiatry·Dilip V JesteCarl Salzman
Jun 21, 2006·Expert Review of Neurotherapeutics·Kimberly H LittrellNicole M Wolf
Sep 4, 2007·The British Journal of Psychiatry : the Journal of Mental Science·R A Rosenheck
Feb 23, 2019·Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie·Lucia RicciardiMark Edwards
May 9, 2012·Journal of Clinical Psychopharmacology·Bruce J KinonHong Liu-Seifert
Aug 15, 2021·Neuropsychopharmacology Reports·UNKNOWN Japanese Society of Neuropsychopharmacology

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here